---
title: "Annexon Stockholders Approve Directors, Compensation and Share Increase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289645814.md"
description: "Annexon Biosciences shareholders approved director elections, executive compensation, KPMG appointment, and increased authorized shares to 500 million at the June 11, 2026 meeting. Analysts maintain a 'Hold' rating with a $7.00 target. TipRanks AI 'Spark' rates ANNX as Neutral, citing weak financials, pre-revenue status, net losses, and cash burn risks despite its focus on complement system therapies."
datetime: "2026-06-12T22:27:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289645814.md)
  - [en](https://longbridge.com/en/news/289645814.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289645814.md)
---

# Annexon Stockholders Approve Directors, Compensation and Share Increase

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Annexon Biosciences ( (ANNX) ) just unveiled an update.

Annexon, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders elected Bettina M. Cockroft, M.D., and Douglas Love, Esq., as Class III directors to serve three-year terms expiring at the 2029 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers, signaling continued support for current leadership and pay structures.

Investors ratified the Audit Committee’s selection of KPMG LLP as Annexon’s independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing confidence in the company’s financial oversight. Stockholders further approved an amendment to the certificate of incorporation to increase authorized common shares from 300 million to 500 million, expanding Annexon’s flexibility for future capital raising and strategic corporate initiatives.

The most recent analyst rating on (ANNX) stock is a Hold  
with a $7.00 price target.  
To see the full list of analyst forecasts on Annexon Biosciences stock,  
see the ANNX Stock Forecast page.

**Spark’s Take on ANNX Stock**

According to Spark, TipRanks’ AI Analyst, ANNX is a Neutral.

The score is primarily held down by weak financial performance driven by a pre-revenue model, large net losses, and accelerating cash burn that raises funding risk. Technicals are mixed with modest near-term weakness and no strong momentum signal, while valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on ANNX stock,  
click here.

**More about Annexon Biosciences**

Annexon, Inc. is a biopharmaceutical company focused on developing therapies that target the complement system, a key part of the immune response implicated in various autoimmune, neurodegenerative and ophthalmic diseases. The company’s pipeline is directed at serious complement-mediated disorders, positioning it within the specialty biotech segment of the healthcare industry.

**Average Trading Volume:** 2,545,390

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $770.1M

### Related Stocks

- [ANNX.US](https://longbridge.com/en/quote/ANNX.US.md)

## Related News & Research

- [Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead](https://longbridge.com/en/news/289195172.md)
- [Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout](https://longbridge.com/en/news/288679260.md)
- [COIN Stock Alert: What to Know as Coinbase Launches AI Trading Tool](https://longbridge.com/en/news/289629146.md)
- [2 hypergrowth pure-play AI stocks to buy and hold for the next decade](https://longbridge.com/en/news/289371960.md)
- [Forget AI Models. This Company Sells What Every AI Giant Needs.](https://longbridge.com/en/news/289086501.md)